Yuliya A. Efimova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yuliya A. Efimova has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Pavel V. Postnikov
National Anti‐Doping Laboratory (Institute) Lomonosov Moscow State University (NADL MSU) Moscow Russia
12 shared publications - Irina V. Pronina
Emanuel Institute of Biochemical Physics of Russian Academy of Sciences
5 shared publications - Andrey V. Polosin
M.V. Lomonosov Moscow State University, National Anti-Doping Laboratory (Institute) (NADL MSU)
4 shared publications E. S. Mochalova
M.V. Lomonosov Moscow State University, National Anti-Doping Laboratory (Institute) (NADL MSU)
3 shared publications- F. V. Radus
MIREA — Russian Technological University (M.V. Lomonosov Institute of Fine Chemical Technologies)
3 shared publications - D. S. Polyansky
MIREA – Russian Technological University (M.V. Lomonosov Institute of Fine Chemical Technologies)
2 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 21 (4) , 448-458
Quantitative evaluation of meldonium by HPLC–MS/MS in meat of animals injected with Emidonol® and urine samples of volunteers after consumption of this meat in food
Objectives. In recent years, the issue of food contamination with substances on the World Anti-Doping Agency (WADA) Prohibited List has become particularly pressing. Meldonium, prohibited in sport under Article S4.4, may be unintentionally consumed by athletes via the use of the veterinary drug Emidonol ® , approved by the Federal Service for Veterinary and Phytosanitary Surveillance ( Rosselkhoznadzor ), in farm animals. Two studies have already been published on the determination of meldonium in meat samples contaminated with the veterinary drug. However, its concentrations in urine samples obtained from volunteers following heat treatment and consumption of such meat have not yet been determined, nor has the duration of its urinary excretion been studied, both factors being important for rigorous anti-doping control. The present study therefore set out to quantitatively evaluate meldonium in samples of raw meat obtained from calves slaughtered on the 15th ( n = 3) and 30th ( n = 3) days following a course of Emidonol® injections, as well as to study the kinetics of its excretion in urine following the single consumption of 350 g of meat contaminated with it. Methods. Raw meat samples were prepared using methanol–water extraction followed by acetonitrile protein precipitation, while urine samples were prepared using the dilute-and-shoot approach. High-performance liquid chromatography tandem mass spectrometry (HPLC–MS/MS) under electrospray ionization conditions with positive ion detection (ESI+) was used for analysis. Meldonium was identified in selective reaction monitoring (SRM) mode using following SRM transitions and collision energies: 147 > 147 (10), 147 > 58 (17), 147 > 59 (17) for meldonium and 150 > 61 (30) for meldonium-d 3 (Internal Standard). Results. Meldonium concentrations in raw meat samples from calves slaughtered 15 days after completion of the veterinary drug course ranged from 1428 ± 43 to 2627 ± 14 ng per 0.5 g; after 30 days, the corresponding concentrations varied from 922 ± 13 to 1558 ± 28 ng per 0.5 g. Following heat treatment and consumption of the meat samples, maximum concentrations of meldonium in urine reached after 2–5 h following consumption varied depending on the cooking method from 219 ± 2 to 386 ± 1 ng/mL, which significantly exceeds the WADA Minimum Required Performance Level (MRPL). Meldonium was still present in detectable amounts in the urine of volunteers 24–28 h after consumption of the Emidonol® - contaminated meat. Conclusions. The potential for unintended meldonium use in athletes through the consumption of meat from farm animals contaminated with Emidonol® has been demonstrated. The tested levels could lead to a positive doping test and appropriate sanctions against the athlete.
- 10 September 2026
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 21 (4) , 448-458
Open AccessQuantitative evaluation of meldonium by HPLC–MS/MS in meat of animals injected with Emidonol® and urine samples of volunteers after consumption of this meat in food
Objectives. In recent years, the issue of food contamination with substances on the World Anti-Doping Agency (WADA) Prohibited List has become particularly pressing. Meldonium, prohibited in sport under Article S4.4, may be unintentionally consumed by athletes via the use of the veterinary drug Emidonol ® , approved by the Federal Service for Veterinary and Phytosanitary Surveillance ( Rosselkhoznadzor ), in farm animals. Two studies have already been published on the determination of meldonium in meat samples contaminated with the veterinary drug. However, its concentrations in urine samples obtained from volunteers following heat treatment and consumption of such meat have not yet been determined, nor has the duration of its urinary excretion been studied, both factors being important for rigorous anti-doping control. The present study therefore set out to quantitatively evaluate meldonium in samples of raw meat obtained from calves slaughtered on the 15th ( n = 3) and 30th ( n = 3) days following a course of Emidonol® injections, as well as to study the kinetics of its excretion in urine following the single consumption of 350 g of meat contaminated with it. Methods. Raw meat samples were prepared using methanol–water extraction followed by acetonitrile protein precipitation, while urine samples were prepared using the dilute-and-shoot approach. High-performance liquid chromatography tandem mass spectrometry (HPLC–MS/MS) under electrospray ionization conditions with positive ion detection (ESI+) was used for analysis. Meldonium was identified in selective reaction monitoring (SRM) mode using following SRM transitions and collision energies: 147 > 147 (10), 147 > 58 (17), 147 > 59 (17) for meldonium and 150 > 61 (30) for meldonium-d 3 (Internal Standard). Results. Meldonium concentrations in raw meat samples from calves slaughtered 15 days after completion of the veterinary drug course ranged from 1428 ± 43 to 2627 ± 14 ng per 0.5 g; after 30 days, the corresponding concentrations varied from 922 ± 13 to 1558 ± 28 ng per 0.5 g. Following heat treatment and consumption of the meat samples, maximum concentrations of meldonium in urine reached after 2–5 h following consumption varied depending on the cooking method from 219 ± 2 to 386 ± 1 ng/mL, which significantly exceeds the WADA Minimum Required Performance Level (MRPL). Meldonium was still present in detectable amounts in the urine of volunteers 24–28 h after consumption of the Emidonol® - contaminated meat. Conclusions. The potential for unintended meldonium use in athletes through the consumption of meat from farm animals contaminated with Emidonol® has been demonstrated. The tested levels could lead to a positive doping test and appropriate sanctions against the athlete.
- 23 June 2026
- Published by Wiley in Drug Testing and Analysis
- Vol. 18 (9) , 1198-1202
HILIC‐MS/MS Detection of Meldonium in Meat from Emidonol‐Treated Calves and Volunteer Urine After Consumption: An Anti‐Doping Perspective
A pilot study was conducted to detect meldonium in raw meat samples from young calves slaughtered 15 and 30 days ( n = 3 per time‐point) after a 15‐day course of Emidonol. Meldonium concentration was also assessed in meat samples after cooking before consumption, as well as in urine samples from volunteers after consuming a single 350 g portion of cooked meat. Urine was collected over 48 h. The maximum mean estimated meldonium concentrations in raw meat samples were 5250 ng/g on the 15th day after drug treatment and 3110 ng/g on the 30th day after drug treatment. The mean estimated meldonium concentrations in medium‐rare steak cooked for 10 min (15 days after the course) and baked meat were 2960 and 1970 ng/g, respectively; for the “30‐day” samples, these values were 1380 and 760 ng/g. The mean maximum estimated urine meldonium concentrations, which peaked at 2–5 h post‐consumption, were 386 and 344 ng/mL for the “15‐day” meat, and 258 and 219 ng/mL for the “30‐day” meat, respectively. Thus, after eating meat samples contaminated with Emidonol, meldonium can be detected in urine 24–28 h post‐consumption; during the first 2–14 h, its concentration can be even higher than the WADA MRPL level, which may result in an inadvertent adverse analytical finding for meldonium in sports drug testing.
- 23 June 2026
- Published by Wiley in Drug Testing and Analysis
- Vol. 18 (9) , 1198-1202
HILIC‐MS/MS Detection of Meldonium in Meat from Emidonol‐Treated Calves and Volunteer Urine After Consumption: An Anti‐Doping Perspective
A pilot study was conducted to detect meldonium in raw meat samples from young calves slaughtered 15 and 30 days ( n = 3 per time‐point) after a 15‐day course of Emidonol. Meldonium concentration was also assessed in meat samples after cooking before consumption, as well as in urine samples from volunteers after consuming a single 350 g portion of cooked meat. Urine was collected over 48 h. The maximum mean estimated meldonium concentrations in raw meat samples were 5250 ng/g on the 15th day after drug treatment and 3110 ng/g on the 30th day after drug treatment. The mean estimated meldonium concentrations in medium‐rare steak cooked for 10 min (15 days after the course) and baked meat were 2960 and 1970 ng/g, respectively; for the “30‐day” samples, these values were 1380 and 760 ng/g. The mean maximum estimated urine meldonium concentrations, which peaked at 2–5 h post‐consumption, were 386 and 344 ng/mL for the “15‐day” meat, and 258 and 219 ng/mL for the “30‐day” meat, respectively. Thus, after eating meat samples contaminated with Emidonol, meldonium can be detected in urine 24–28 h post‐consumption; during the first 2–14 h, its concentration can be even higher than the WADA MRPL level, which may result in an inadvertent adverse analytical finding for meldonium in sports drug testing.
- Open Access
- 6 May 2026
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 21 (2) , 188-211
Development and scaling of a chromatographic purification technology for single-domain antibodies fused to the Fc fragment of human IgG1
Objectives. The work set out to develop a chromatographic purification technology for drugs based on modified single-domain antibodies specific to the SARS-CoV-2 virus, as well as to select the optimal parameters for the purification process and scale up this technology for production. Methods. The study was conducted on a culture of Chinese hamster ovary (CHO) cells GAMP2C5 clone 78, CHO B5 clone 4, and CHO B10 clone 4, which were used to produce modified single-domain antibodies GAMP2C5, GAMB5, and GAMB10, respectively. Chromatographic purification was performed using AKTA pure 25 and AKTA Pilot 600s chromatographs. Quality control of the obtained drugs was carried out using high-performance liquid chromatography, capillary gel electrophoresis, dynamic light scattering, enzymelinked immunosorbent assay, and polymerase chain reaction. Results. Multimodal chromatography using CA ++ Pure-HA ( TOSOH , Japan) resin based on type 1 ceramic hydroxyapatite can be effectively used for the removal of aggregated antibody forms. The drugs obtained after chromatography using CA ++ Pure-HA resin based on type 1 ceramic hydroxyapatite have a purity of more than 97%. The developed purification technology was scaled up to purify 200 L of culture fluid after cultivation in an STR 200 bioreactor. Conclusions. The described technology developed for purifying modified mono-domain antibodies using the CA ++ Pure-HA multimodal resin based on type 1 ceramic hydroxyapatite allows for the effective removal of low-molecular-weight impurities and aggregated forms of the antibody. The antibodies obtained using the developed technology are characterized by a high degree of purity and the absence of various impurities (residual protein of the producer strain, residual protein A, and residual DNA of the producer strain), as well as offering a hydrodynamic molecular radius corresponding to the theoretical value of monomeric forms of antibodies.
- 6 May 2026
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 21 (2) , 188-211
Open AccessDevelopment and scaling of a chromatographic purification technology for single-domain antibodies fused to the Fc fragment of human IgG1
Objectives. The work set out to develop a chromatographic purification technology for drugs based on modified single-domain antibodies specific to the SARS-CoV-2 virus, as well as to select the optimal parameters for the purification process and scale up this technology for production. Methods. The study was conducted on a culture of Chinese hamster ovary (CHO) cells GAMP2C5 clone 78, CHO B5 clone 4, and CHO B10 clone 4, which were used to produce modified single-domain antibodies GAMP2C5, GAMB5, and GAMB10, respectively. Chromatographic purification was performed using AKTA pure 25 and AKTA Pilot 600s chromatographs. Quality control of the obtained drugs was carried out using high-performance liquid chromatography, capillary gel electrophoresis, dynamic light scattering, enzymelinked immunosorbent assay, and polymerase chain reaction. Results. Multimodal chromatography using CA ++ Pure-HA ( TOSOH , Japan) resin based on type 1 ceramic hydroxyapatite can be effectively used for the removal of aggregated antibody forms. The drugs obtained after chromatography using CA ++ Pure-HA resin based on type 1 ceramic hydroxyapatite have a purity of more than 97%. The developed purification technology was scaled up to purify 200 L of culture fluid after cultivation in an STR 200 bioreactor. Conclusions. The described technology developed for purifying modified mono-domain antibodies using the CA ++ Pure-HA multimodal resin based on type 1 ceramic hydroxyapatite allows for the effective removal of low-molecular-weight impurities and aggregated forms of the antibody. The antibodies obtained using the developed technology are characterized by a high degree of purity and the absence of various impurities (residual protein of the producer strain, residual protein A, and residual DNA of the producer strain), as well as offering a hydrodynamic molecular radius corresponding to the theoretical value of monomeric forms of antibodies.
- 29 January 2026
- Published by Wiley in Drug Testing and Analysis
- Vol. 18 (3) , 414-418
Emoxypine as a Potential Marker for Identifying Possible Cases of Unintended Meldonium Doping in Sports
In recent years, a scenario involving milk contamination by biotransformation products of the veterinary drug Emidonol has received widespread publicity. Emidonol is intended for use in cattle under pathological conditions accompanied by hypoxia. The drug dissociates into two antihypoxants—meldonium, a metabolic modulator prohibited in sports, and emoxypine, which also has antioxidant properties. A small‐scale pilot study involved three volunteers consuming a single 900‐mL dose of unpasteurized cow's milk collected on the last (15th) day of treatment with the drug. The mean estimated urinary concentration of emoxypine peaked between 7‐ and 8.5‐h postadministration (1360 ± 240 ng/mL), elimination time being approximately 50–54 h. The mean estimated urinary concentration of meldonium peaked between 5.8‐ and 9.0‐h postadministration and was 322 ± 68 ng/mL, elimination time being approximately 35–45 h. The simultaneous presence of emoxypine and meldonium in urine samples may be indicative of the consumption of Emidonol‐contaminated milk, which may facilitate the identification of cases of unintended doping in sport.
- 29 January 2026
- Published by Wiley in Drug Testing and Analysis
- Vol. 18 (3) , 414-418
Emoxypine as a Potential Marker for Identifying Possible Cases of Unintended Meldonium Doping in Sports
In recent years, a scenario involving milk contamination by biotransformation products of the veterinary drug Emidonol has received widespread publicity. Emidonol is intended for use in cattle under pathological conditions accompanied by hypoxia. The drug dissociates into two antihypoxants—meldonium, a metabolic modulator prohibited in sports, and emoxypine, which also has antioxidant properties. A small‐scale pilot study involved three volunteers consuming a single 900‐mL dose of unpasteurized cow's milk collected on the last (15th) day of treatment with the drug. The mean estimated urinary concentration of emoxypine peaked between 7‐ and 8.5‐h postadministration (1360 ± 240 ng/mL), elimination time being approximately 50–54 h. The mean estimated urinary concentration of meldonium peaked between 5.8‐ and 9.0‐h postadministration and was 322 ± 68 ng/mL, elimination time being approximately 35–45 h. The simultaneous presence of emoxypine and meldonium in urine samples may be indicative of the consumption of Emidonol‐contaminated milk, which may facilitate the identification of cases of unintended doping in sport.
- Open Access
- 2 September 2025
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 20 (4) , 382-398
Semiquantitative determination of meldonium and emoxypine in human urine by HPLC–MS/MS after receiving a single therapeutic dose of Brainmax® and milk from cows receiving a preventive course of Emidonol®
Objectives. Emidonol® is a veterinary drug used to treat pathological conditions associated with hypoxia in cattle. In addition tomeldonium, which is included in the Prohibited List of the World Anti-Doping Agency, the biotransformation product of Emidonol® in animals is the antioxidant and antihypoxant emoxypine, which can act as a marker of contamination of food products with the above-mentioned widely known metabolic modulator. The study set out to semiquantitatively determine emoxypine and meldonium levels, as well as to compare the excretion profiles of these substances by high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) in urine samples of volunteers after receiving a single oral administration of a therapeutic dose of Brainmax® and after consuming a large amount of milk from cows that had received a prophylactic course of Emidonol®.Methods. Sample preparation of urine samples for the determination of meldonium was carried out using the “dilute and shoot” approach. Enzymatic hydrolysis with β-glucuronidase followed by purification by solid-phase extraction was used to determine emoxypine. Identification of meldonium and emoxypine was carried out by HPLC–MS/MS under conditions of electrospray ionization with registration of positively charged ions in the selective reaction monitoring (SRM) mode for the following transitions and collision energies: for meldonium, 147.1 > 147.1 (15), 147.1 > 132.1 (17), 147.1 > 58.1 (17), 147.1 > 59.1 (17), 147.1 > 42.1 (60); for emoxypine, 138.1 > 138.1 (7), 138.1 > 123.1 (15), 138.1 > 110.1 (20), 138.1 > 95.1 (20).Results. The possibility of simultaneous identifying meldonium and emoxypine obtained after enzymatic hydrolysis with β-glucuronidase in urine samples of volunteers after oral intake of single dose of Brainmax® and consuming a large amount of Emidonol®-contaminated milk using the HPLC–MS/MS method with different numbers and variants of SRM transitions was demonstrated. Differences in the excretion profiles of these substances were found after ingestion of large amounts of contaminated milk and a single oral dose of Brainmax® 15–18 h later and further. After taking contaminated milk 12 h or more later, emoxypine is detected in concentrations 5 or more times higher than meldonium concentrations and is excreted for a longer period of time. Conversely, after taking a single dose of Brainmax®, which contains both substances, the content of meldonium in urine samples of volunteers 15–18 h after taking it is several times higher in relation to emoxypine. The constant ratio of estimated concentrations of meldonium and emoxypine in Emidonol® was found to be approximately 1 : 2.Conclusions. Identification of meldonium in the presence of emoxypine in urine under certain conditions can be used to distinguish contamination of food products with a prohibited metabolic modulator from intentional ingestion of real doping.
- 2 September 2025
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 20 (4) , 382-398
Open AccessSemiquantitative determination of meldonium and emoxypine in human urine by HPLC–MS/MS after receiving a single therapeutic dose of Brainmax® and milk from cows receiving a preventive course of Emidonol®
Objectives. Emidonol® is a veterinary drug used to treat pathological conditions associated with hypoxia in cattle. In addition tomeldonium, which is included in the Prohibited List of the World Anti-Doping Agency, the biotransformation product of Emidonol® in animals is the antioxidant and antihypoxant emoxypine, which can act as a marker of contamination of food products with the above-mentioned widely known metabolic modulator. The study set out to semiquantitatively determine emoxypine and meldonium levels, as well as to compare the excretion profiles of these substances by high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) in urine samples of volunteers after receiving a single oral administration of a therapeutic dose of Brainmax® and after consuming a large amount of milk from cows that had received a prophylactic course of Emidonol®.Methods. Sample preparation of urine samples for the determination of meldonium was carried out using the “dilute and shoot” approach. Enzymatic hydrolysis with β-glucuronidase followed by purification by solid-phase extraction was used to determine emoxypine. Identification of meldonium and emoxypine was carried out by HPLC–MS/MS under conditions of electrospray ionization with registration of positively charged ions in the selective reaction monitoring (SRM) mode for the following transitions and collision energies: for meldonium, 147.1 > 147.1 (15), 147.1 > 132.1 (17), 147.1 > 58.1 (17), 147.1 > 59.1 (17), 147.1 > 42.1 (60); for emoxypine, 138.1 > 138.1 (7), 138.1 > 123.1 (15), 138.1 > 110.1 (20), 138.1 > 95.1 (20).Results. The possibility of simultaneous identifying meldonium and emoxypine obtained after enzymatic hydrolysis with β-glucuronidase in urine samples of volunteers after oral intake of single dose of Brainmax® and consuming a large amount of Emidonol®-contaminated milk using the HPLC–MS/MS method with different numbers and variants of SRM transitions was demonstrated. Differences in the excretion profiles of these substances were found after ingestion of large amounts of contaminated milk and a single oral dose of Brainmax® 15–18 h later and further. After taking contaminated milk 12 h or more later, emoxypine is detected in concentrations 5 or more times higher than meldonium concentrations and is excreted for a longer period of time. Conversely, after taking a single dose of Brainmax®, which contains both substances, the content of meldonium in urine samples of volunteers 15–18 h after taking it is several times higher in relation to emoxypine. The constant ratio of estimated concentrations of meldonium and emoxypine in Emidonol® was found to be approximately 1 : 2.Conclusions. Identification of meldonium in the presence of emoxypine in urine under certain conditions can be used to distinguish contamination of food products with a prohibited metabolic modulator from intentional ingestion of real doping.
- Open Access
- 10 July 2025
- Published by Ural Federal University in Аналитика и контроль
- Vol. 29 (2) , 125-133
Application of “omics” technologies for anti-doping control in the last years
The large-scale crisis in international sports caused by the spread of coronavirus has led to a deterioration in the physical fitness of athletes, which has contributed to an increase in the possibility of taking prohibited substances and methods. Recent scientific advances in the field of "omics" technologies create potential risks of their use to improve athletic performance. Research on the development of new analytical approaches and methods for identifying doping based on the latest advances in transcriptomics, proteomics, genomics and metabolomics has become relevant. The review summarizes and analyzes new analytical approaches to detecting substances and methods prohibited in sports based on "omics" technologies. The results of the studies can be used to improve the quality and effectiveness of modern doping control.
- 10 July 2025
- Published by Ural Federal University in Аналитика и контроль
- Vol. 29 (2) , 125-133
Open AccessApplication of “omics” technologies for anti-doping control in the last years
The large-scale crisis in international sports caused by the spread of coronavirus has led to a deterioration in the physical fitness of athletes, which has contributed to an increase in the possibility of taking prohibited substances and methods. Recent scientific advances in the field of "omics" technologies create potential risks of their use to improve athletic performance. Research on the development of new analytical approaches and methods for identifying doping based on the latest advances in transcriptomics, proteomics, genomics and metabolomics has become relevant. The review summarizes and analyzes new analytical approaches to detecting substances and methods prohibited in sports based on "omics" technologies. The results of the studies can be used to improve the quality and effectiveness of modern doping control.
- Open Access
- 3 November 2024
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 19 (5) , 393-407
Identification of hypoxene metabolites in urine samples using gas chromatography–tandem mass spectrometry for anti-doping control
Objectives. Hypoxen is a drug which possesses antioxidant and antihypoxic effects. It achieves this by increasing the utilization of oxygen by mitochondria, intensifying oxidative phosphorylation, and as a result, improving tissue respiration. Athletes take it during prolonged exercise, in order to increase efficiency and reduce physical overwork. Since 2023, the World Anti-Doping Agency has included the drug in the monitoring program, in the belief that it can be used to gain a competitive advantage. It is thus a candidate for inclusion in the Prohibited List as a potential regulator of the human metabolism. Currently, there are no studies or scientific publications focusing on the identification of hypoxene in biofluids for the purpose of anti-doping control. The aim of this study is to determine the possible metabolites of the drug and their chromato-mass spectrometric characteristics in urine samples using gas chromatography–tandem mass spectrometry (GC–MS/MS) for doping control screening purposes.Methods. Sample preparation of urine samples was carried out using enzymatic hydrolysis, liquid–liquid extraction and derivatization. The GC–MS/MS method was used for analysis. Screening of hypoxene metabolites was carried out in the mode of total ion current after fragmentation of selected parent ions.Results. Three specific metabolites of hypoxene (m/z 342, 300, and 346, including trimethylsilyl derivatives) were identified in urine samples of volunteers (n = 3). They can act as markers for taking the target antihypoxant, and their possible structural formulas are given. The excretion curves of two metabolites with an m/z of 300 and 346 respectively in urine were studied. The maximum concentration is reached after 8–14 and 1.5–6 h, respectively. It was established, that these metabolites are reliably identified in urine 90 h or more after a single dose of the drug.Conclusions. Possible structures of hypoxene metabolites in urine samples from volunteers were determined for the first time and their chromato-mass spectrometric characteristics were established. The approach developed in this study can be used for screening analysis of hypoxene for the purpose of anti-doping control.
- 3 November 2024
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 19 (5) , 393-407
Open AccessIdentification of hypoxene metabolites in urine samples using gas chromatography–tandem mass spectrometry for anti-doping control
Objectives. Hypoxen is a drug which possesses antioxidant and antihypoxic effects. It achieves this by increasing the utilization of oxygen by mitochondria, intensifying oxidative phosphorylation, and as a result, improving tissue respiration. Athletes take it during prolonged exercise, in order to increase efficiency and reduce physical overwork. Since 2023, the World Anti-Doping Agency has included the drug in the monitoring program, in the belief that it can be used to gain a competitive advantage. It is thus a candidate for inclusion in the Prohibited List as a potential regulator of the human metabolism. Currently, there are no studies or scientific publications focusing on the identification of hypoxene in biofluids for the purpose of anti-doping control. The aim of this study is to determine the possible metabolites of the drug and their chromato-mass spectrometric characteristics in urine samples using gas chromatography–tandem mass spectrometry (GC–MS/MS) for doping control screening purposes.Methods. Sample preparation of urine samples was carried out using enzymatic hydrolysis, liquid–liquid extraction and derivatization. The GC–MS/MS method was used for analysis. Screening of hypoxene metabolites was carried out in the mode of total ion current after fragmentation of selected parent ions.Results. Three specific metabolites of hypoxene (m/z 342, 300, and 346, including trimethylsilyl derivatives) were identified in urine samples of volunteers (n = 3). They can act as markers for taking the target antihypoxant, and their possible structural formulas are given. The excretion curves of two metabolites with an m/z of 300 and 346 respectively in urine were studied. The maximum concentration is reached after 8–14 and 1.5–6 h, respectively. It was established, that these metabolites are reliably identified in urine 90 h or more after a single dose of the drug.Conclusions. Possible structures of hypoxene metabolites in urine samples from volunteers were determined for the first time and their chromato-mass spectrometric characteristics were established. The approach developed in this study can be used for screening analysis of hypoxene for the purpose of anti-doping control.
- Open Access
- 6 July 2024
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 19 (3) , 232-239
Methylation of a group of microRNA genes as a marker for the diagnosis and prognosis of non-small cell lung cancer
Objectives. Lung cancer, representing a difficult-to-diagnose heterogeneous malignant neoplasm, is characterized by an asymptomatic course up to late stages, a high incidence of adverse outcomes, and a high probability of metastasis. Its most common form is non-small cell lung cancer (NSCLC). Recent studies have demonstrated a significant role of non-coding RNAs—in particular, microRNAs—in the development of NSCLC. MicroRNAs, which function as post-transcriptional regulators of the expression of protein-coding genes, including those associated with oncogenesis, are involved in the processes of cell proliferation, differentiation, and apoptosis. One of the approaches for regulating the expression of microRNAs themselves is to change the methylation of the CpG island adjacent to the microRNA gene or overlapping it. It has been shown that microRNA genes are several times more likely to undergo methylation than protein-coding genes. The aim of the present work is to study changes in the level of methylation of a number of microRNA genes and compile a potential panel of markers for the diagnosis and prognosis of NSCLC.Methods. Samples of NSCLC tumors were collected and clinically characterized at the Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia. High-molecular-weight DNA was isolated from tissues using a standard method. The level of methylation was analyzed using bisulfite conversion of DNA and quantitative methyl-specific polymerase chain reaction with real-time detection. The significance of differences between the studied groups was assessed by the nonparametric Mann–Whitney U test for independent samples. Differences were considered significant at p < 0.05.Results. The analysis of methylation levels of microRNA genes revealed a significant (p < 0.05) increase in the methylation level of eight microRNA genes: MIR124-1/2/3, MIR125В-1, MIR129-2, MIR137, MIR375, MIR1258, and MIR339 (p < 0.01, false discovery rate ≤ 0.25). On the basis of receiver operating characteristic analysis, a panel of markers is proposed for the diagnosis of NSCLC according to the nature of methylation of the studied microRNA genes in the tumor and in the normal tissue.Conclusions. Our results, which contribute to the understanding of molecular mechanisms involved in NSCLC development, can be used in the development of new diagnostic and prognostic approaches in clinical oncology.
- 6 July 2024
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 19 (3) , 232-239
Open AccessMethylation of a group of microRNA genes as a marker for the diagnosis and prognosis of non-small cell lung cancer
Objectives. Lung cancer, representing a difficult-to-diagnose heterogeneous malignant neoplasm, is characterized by an asymptomatic course up to late stages, a high incidence of adverse outcomes, and a high probability of metastasis. Its most common form is non-small cell lung cancer (NSCLC). Recent studies have demonstrated a significant role of non-coding RNAs—in particular, microRNAs—in the development of NSCLC. MicroRNAs, which function as post-transcriptional regulators of the expression of protein-coding genes, including those associated with oncogenesis, are involved in the processes of cell proliferation, differentiation, and apoptosis. One of the approaches for regulating the expression of microRNAs themselves is to change the methylation of the CpG island adjacent to the microRNA gene or overlapping it. It has been shown that microRNA genes are several times more likely to undergo methylation than protein-coding genes. The aim of the present work is to study changes in the level of methylation of a number of microRNA genes and compile a potential panel of markers for the diagnosis and prognosis of NSCLC.Methods. Samples of NSCLC tumors were collected and clinically characterized at the Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia. High-molecular-weight DNA was isolated from tissues using a standard method. The level of methylation was analyzed using bisulfite conversion of DNA and quantitative methyl-specific polymerase chain reaction with real-time detection. The significance of differences between the studied groups was assessed by the nonparametric Mann–Whitney U test for independent samples. Differences were considered significant at p < 0.05.Results. The analysis of methylation levels of microRNA genes revealed a significant (p < 0.05) increase in the methylation level of eight microRNA genes: MIR124-1/2/3, MIR125В-1, MIR129-2, MIR137, MIR375, MIR1258, and MIR339 (p < 0.01, false discovery rate ≤ 0.25). On the basis of receiver operating characteristic analysis, a panel of markers is proposed for the diagnosis of NSCLC according to the nature of methylation of the studied microRNA genes in the tumor and in the normal tissue.Conclusions. Our results, which contribute to the understanding of molecular mechanisms involved in NSCLC development, can be used in the development of new diagnostic and prognostic approaches in clinical oncology.
- Open Access
- 24 March 2024
- Published by National Alliance of Medicine and Sports - Healthy Generation in Sports medicine: research and practice
- Vol. 13 (4) , 54-64
MiR-378a-3p and miR-491-5p as markers of xenon abuse in doping control
Xenon stimulates the synthesis of the hormone erythropoietin, which leads to improved oxygen supply to tissues, increased endurance and can be used by athletes to gain an undue advantage in competitions. The World Anti-Doping Agency (WADA) banned its use. The determination of xenon in biological fluids, in particular, in blood plasma samples, is difficult due to the narrow detection window. Its indirect detection is possible by changing in some blood parameters during a clinical analysis (RET%, HGB, HCT, etc.), however, this analysis is nonspecific and the use of other erythropoiesis-stimulating agents can lead to similar changes.Aims: The aim of the study was to search for long-term microRNA markers, the expression of which is specific and markedly altered by inhaled xenon.Methods: Quantitative real-time PCR was performed on CFX96 Bio-Rad analyser using miRCURY® LNA® miRNA SYBR® Green PCR Kit and panels for studying the expression profiles of mature microRNAs of the hypoxia signaling pathway miRCURY LNA™ miRNA Focus Panel.Results: Based on statistical data analysis, it was found that the expression of hsa-miR-378a-3p and hsa-miR-491-5p in blood plasma increases significantly (more than 70 times) when xenon inhalations are used as an erythropoiesis stimulator. Measurement of hematological parameters before and after inhalation showed no significant changes that could affect endurance or give competitive advantages.Conclusion: The evaluated difference in microRNA expression levels before and after administration of the xenon mixture (Xe/O2) makes hsa-miR-378a-3p and hsa-miR-491-5p potential candidates for the role of long-term markers of xenon abuse.
- 24 March 2024
- Published by National Alliance of Medicine and Sports - Healthy Generation in Sports medicine: research and practice
- Vol. 13 (4) , 54-64
Open AccessMiR-378a-3p and miR-491-5p as markers of xenon abuse in doping control
Xenon stimulates the synthesis of the hormone erythropoietin, which leads to improved oxygen supply to tissues, increased endurance and can be used by athletes to gain an undue advantage in competitions. The World Anti-Doping Agency (WADA) banned its use. The determination of xenon in biological fluids, in particular, in blood plasma samples, is difficult due to the narrow detection window. Its indirect detection is possible by changing in some blood parameters during a clinical analysis (RET%, HGB, HCT, etc.), however, this analysis is nonspecific and the use of other erythropoiesis-stimulating agents can lead to similar changes.Aims: The aim of the study was to search for long-term microRNA markers, the expression of which is specific and markedly altered by inhaled xenon.Methods: Quantitative real-time PCR was performed on CFX96 Bio-Rad analyser using miRCURY® LNA® miRNA SYBR® Green PCR Kit and panels for studying the expression profiles of mature microRNAs of the hypoxia signaling pathway miRCURY LNA™ miRNA Focus Panel.Results: Based on statistical data analysis, it was found that the expression of hsa-miR-378a-3p and hsa-miR-491-5p in blood plasma increases significantly (more than 70 times) when xenon inhalations are used as an erythropoiesis stimulator. Measurement of hematological parameters before and after inhalation showed no significant changes that could affect endurance or give competitive advantages.Conclusion: The evaluated difference in microRNA expression levels before and after administration of the xenon mixture (Xe/O2) makes hsa-miR-378a-3p and hsa-miR-491-5p potential candidates for the role of long-term markers of xenon abuse.
- Open Access
- 20 March 2023
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 18 (1) , 65–74
Determination of possible microRNA-markers of cobalt abuse by real-time qPCR using hypoxia signaling pathway panels
Objectives. Cobalt mimics the state of hypoxia to prevent degradation of the alpha subunit of hypoxia-inducible factor, resulting in an increase in blood oxygen capacity and endurance. Athletes can use this property to gain competitive advantage. Nowadays, direct methods of inductively coupled plasma mass spectrometry and liquid chromatography-tandem mass spectrometry are used to determine total cobalt levels in the body. However, the World Anti-Doping Agency is yet to establish a maximum allowable threshold concentration of this element in biofluids. The lack of clear identification criteria complicates the interpretation of the obtained results for the purposes of doping control. In this regard, the present work proposes a new approach for the indirect determination of possible cobalt abuse based on changes in the expression levels of miRNAs involved in the regulation of hypoxia signaling pathways. Here, the aim is to identify possible microRNA markers whose expression does not depend on exercise-induced hypoxia, but changes markedly when taking cobalt preparations.Methods. MicroRNA isolation was performed from blood plasma samples using the PAXgene Blood miRNA Kit. Quantitative real-time polymerase chain reaction (PCR) was performed on CFX96 Bio-Rad (USA) analyzer using miScript® SYBR® Green PCR Kits and panels for studying the expression profiles of mature microRNAs of the hypoxia signaling pathway miScript® miRNA PCR Array.Results. Based on the statistical analysis of the data, it was found that the expression of hsa-miR-15b-5p in the blood plasma of the subjects does not depend on physical activity, but increases when taking cobalt preparations.Conclusions. The difference in expression levels during anaerobic exercise-induced hypoxia and cobalt-induced hypoxia makes hsa-miR-15b-5p a potential candidate to be a marker of erythropoiesis-stimulating agent abuse.
- 20 March 2023
- Published by RTU MIREA in Fine Chemical Technologies
- Vol. 18 (1) , 65–74
Open AccessDetermination of possible microRNA-markers of cobalt abuse by real-time qPCR using hypoxia signaling pathway panels
Objectives. Cobalt mimics the state of hypoxia to prevent degradation of the alpha subunit of hypoxia-inducible factor, resulting in an increase in blood oxygen capacity and endurance. Athletes can use this property to gain competitive advantage. Nowadays, direct methods of inductively coupled plasma mass spectrometry and liquid chromatography-tandem mass spectrometry are used to determine total cobalt levels in the body. However, the World Anti-Doping Agency is yet to establish a maximum allowable threshold concentration of this element in biofluids. The lack of clear identification criteria complicates the interpretation of the obtained results for the purposes of doping control. In this regard, the present work proposes a new approach for the indirect determination of possible cobalt abuse based on changes in the expression levels of miRNAs involved in the regulation of hypoxia signaling pathways. Here, the aim is to identify possible microRNA markers whose expression does not depend on exercise-induced hypoxia, but changes markedly when taking cobalt preparations.Methods. MicroRNA isolation was performed from blood plasma samples using the PAXgene Blood miRNA Kit. Quantitative real-time polymerase chain reaction (PCR) was performed on CFX96 Bio-Rad (USA) analyzer using miScript® SYBR® Green PCR Kits and panels for studying the expression profiles of mature microRNAs of the hypoxia signaling pathway miScript® miRNA PCR Array.Results. Based on the statistical analysis of the data, it was found that the expression of hsa-miR-15b-5p in the blood plasma of the subjects does not depend on physical activity, but increases when taking cobalt preparations.Conclusions. The difference in expression levels during anaerobic exercise-induced hypoxia and cobalt-induced hypoxia makes hsa-miR-15b-5p a potential candidate to be a marker of erythropoiesis-stimulating agent abuse.